Beatrix Stelte‐Ludwig

902 total citations
39 papers, 574 citations indexed

About

Beatrix Stelte‐Ludwig is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Beatrix Stelte‐Ludwig has authored 39 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Beatrix Stelte‐Ludwig's work include Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (8 papers) and Cell Adhesion Molecules Research (7 papers). Beatrix Stelte‐Ludwig is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), HER2/EGFR in Cancer Research (8 papers) and Cell Adhesion Molecules Research (7 papers). Beatrix Stelte‐Ludwig collaborates with scholars based in Germany, United States and Canada. Beatrix Stelte‐Ludwig's co-authors include Joachim Hütter, Peter Sandner, Hanna Tinel, Christoph A. Schatz, Sven Golfier, Karl Ziegelbauer, Charlotte Kopitz, Antje Kahnert, Lars Lindén and Beate Müller‐Tiemann and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Beatrix Stelte‐Ludwig

39 papers receiving 552 citations

Peers

Countries citing papers authored by Beatrix Stelte‐Ludwig

Since Specialization

Citations

This map shows the geographic impact of Beatrix Stelte‐Ludwig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatrix Stelte‐Ludwig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatrix Stelte‐Ludwig more than expected).

Fields of papers citing papers by Beatrix Stelte‐Ludwig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatrix Stelte‐Ludwig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatrix Stelte‐Ludwig. The network helps show where Beatrix Stelte‐Ludwig may publish in the future.

Co-authorship network of co-authors of Beatrix Stelte‐Ludwig

This figure shows the co-authorship network connecting the top 25 collaborators of Beatrix Stelte‐Ludwig. A scholar is included among the top collaborators of Beatrix Stelte‐Ludwig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatrix Stelte‐Ludwig. Beatrix Stelte‐Ludwig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Melanie M. Frigault, Beatrix Stelte‐Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran	1
2	Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment 2024 ·Frontiers in Pharmacology ·(unknown), Mareike M. Wiedmann, Beatrix Stelte‐Ludwig, Harvey Wong, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy, Hans‐Georg Lerchen	2
3	Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody 2024 ·Clinical and Experimental Medicine ·Helge G. Roider, Sabine Hoff, Su-Yi Tseng, Sandra Berndt, Mark Trautwein, (unknown), (unknown), J. Camps, Wiebke Nadler, (unknown), Philipp Ellinger, Theresa Pesch, (unknown), (unknown), (unknown), Beatrix Stelte‐Ludwig, Mátyás Gorjánácz	10
4	Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription 2023 ·Cancer Research Communications ·Melanie M. Frigault, (unknown), Harvey Wong, Beatrix Stelte‐Ludwig, (unknown), (unknown), Joseph Birkett, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy	7
5	Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors 2023 ·Cancers ·Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, Mélanie Héroult, (unknown), Kersten M. Gericke, Harvey Wong, Melanie M. Frigault, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy	8
6	Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model 2023 ·Blood ·Tibor Schomber, Beatrix Stelte‐Ludwig, (unknown), Oliver von Ahsen, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy	1
7	Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children 2023 ·Cancer Research ·(unknown), (unknown), Melanie M. Frigault, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte‐Ludwig, (unknown), Anne‐Marie Langevin, Norman J. Lacayo, Aru Narendran	1
8	Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy 2022 ·Cancer Research ·Melanie M. Frigault, Hermes Garbán, Joy M. Greer, (unknown), Raquel Izumi, Amy J. Johnson, Beatrix Stelte‐Ludwig, Ahmed Hamdy	1
9	Abstract 4825: Preclinical characterization of BAY-924, a first in class ADC targeting CXCR5-positive B-cell malignancies, with a KSP inhibitor as novel payload 2019 ·Cancer Research ·(unknown), Stefanie Hammer, (unknown), Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, (unknown), Oliver von Ahsen, Christoph A. Schatz, Simone Greven, Christoph Mahlert, Dominik Mumberg, Pascale Lejeune	1
10	Abstract 46: Preclinical activity of novel antibody-drug conjugates with pyrrole-based kinesin spindle protein inhibitors targeting different tumor antigens 2017 ·Cancer Research ·Anette Sommer, Sandra Berndt, Hans‐Georg Lerchen, Beatrix Stelte‐Ludwig, (unknown), (unknown), Lisa Dietz, Christoph Mahlert, Simone Greven, Nils Griebenow, (unknown), Rolf Jautelat, Heiner Apeler, Bertolt Kreft	1
11	Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect 2014 ·Molecular Cancer Therapeutics ·Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A. Schatz, Beatrix Stelte‐Ludwig, Anke Mayer‐Bartschmid, Kerstin Unterschemmann, (unknown), Lars Lindén, Axel Harrenga, Peter Hauff, Frank-Detlef Scholle, Beate Müller‐Tiemann, Bertolt Kreft, Karl Ziegelbauer	191
12	Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform 2014 ·mAbs ·Thomas Schirrmann, André Frenzel, Lars Lindén, Beatrix Stelte‐Ludwig, Jörg Willuda, Axel Harrenga, Stefan Dübel, Beate Müller‐Tiemann, Mark Trautwein	8
13	Abstract 1754: Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): Characterization and anti-tumor activity in mesothelin-positive preclinical tumor models 2011 ·Cancer Research ·Sven Golfier, Antje Kahnert, Iring Heisler, Charlotte Kopitz, (unknown), Beatrix Stelte‐Ludwig, Anke Mayer‐Bartschmid, (unknown), Lars Lindén, Axel Harrenga, Christoph A. Schatz, Bertolt Kreft, Beate Müller‐Tiemann, Karl Ziegelbauer	5
14	Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides 2007 ·Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Michael Härter, (unknown), Delf Schmidt, Beatrix Stelte‐Ludwig, Ulf Brüggemeier, Andrea Vaupel, Jörg Keldenich, Klemens Lustig, Hideki Tsujishita, Christoph Gerdes	17
15	PDE5-Inhibitoren zur Behandlung des benignen Prostatasyndroms 2007 ·Der Urologe ·Peter Sandner, Hanna Tinel, Beatrix Stelte‐Ludwig, (unknown), D. Neuser, Erwin Bischoff, Ernst Ulbrich	1
16	The use of PDE5 inhibitors in the treatment of benign prostate hyperplasia and lower urinary tract symptoms: preclinical evidences 2007 ·BMC Pharmacology ·Peter Sandner, Hanna Tinel, Beatrix Stelte‐Ludwig, Erwin Bischoff, (unknown)	1
17	Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms 2006 ·British Journal of Urology ·Hanna Tinel, Beatrix Stelte‐Ludwig, Joachim Hütter, Peter Sandner	136
18	Solid phase synthesis of an extensively focused library of thiadiazole ethers 2004 ·Tetrahedron ·Josef Pernerstorfer, Michael Brands, Hartmut Schirok, Beatrix Stelte‐Ludwig, (unknown)	3
19	Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas 2003 ·Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Michael Härter, Andrea Vaupel, (unknown), Delf Schmidt, Ulf Brüggemeier, Beatrix Stelte‐Ludwig, Christoph Gerdes, Hideki Tsujishita	17
20	Biphenyls as potent vitronectin receptor antagonists 2002 ·Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Michael Härter, (unknown), Delf Schmidt, Beatrix Stelte‐Ludwig, Ulf Brüggemeier, Andrea Vaupel, Christoph Gerdes	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact